✉ Email this page to a colleague
« Back to Dashboard
Bevasiranib is an investigational drug.
There have been 5 clinical trials for Bevasiranib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Macular Degeneration, Macular Edema, and Edema. The leading clinical trial sponsors are OPKO Health, Inc. and [disabled in preview].
Recent Clinical Trials for Bevasiranib
|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)||OPKO Health, Inc.||Phase 3|
|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD||OPKO Health, Inc.||Phase 3|
|Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema||OPKO Health, Inc.||Phase 2|